MedTrace Logo

DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)

NCT00865683 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-07-15

No results posted yet for this study

Summary

Women with excess adiposity while pregnant are more likely to develop gestational diabetes and high blood pressure during pregnancy than women of healthy weights. This may occur because overweight and obese pregnant women are less sensitive to insulin and have more inflammation than pregnant women of healthy weights. This study will examine the effect of a nutritional supplement, docosahexaenoic acid (DHA), on improving insulin sensitivity and lessening inflammation in overweight and obese pregnant women.

Conditions

  • Overweight and Obesity
  • Insulin Resistance
  • Diabetes, Gestational
  • Hypertension in Pregnancy
  • Pre-Eclampsia

Interventions

DIETARY_SUPPLEMENT

DHA Supplements

Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).

DIETARY_SUPPLEMENT

Placebo Supplements

Participants will receive placebo supplements each day for approximately 3 months (until they give birth).

Sponsors & Collaborators

  • Office of Research on Women's Health (ORWH)

    collaborator NIH

  • Mead Johnson Nutrition

    collaborator INDUSTRY

  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Debra A. Krummel, PhD, RD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865683 on ClinicalTrials.gov